IN182468B - - Google Patents

Info

Publication number
IN182468B
IN182468B IN102MA1996A IN182468B IN 182468 B IN182468 B IN 182468B IN 102MA1996 A IN102MA1996 A IN 102MA1996A IN 182468 B IN182468 B IN 182468B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Barry Howard Carter
Jane Muse Partin
Peter Gregory Varlashkin
Richard Augustus Winnike
William Bayne Grubb Iii
Gregory Alan Conway
Philip George Lake
David Michael Skinner
David James Whatrup
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN182468(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IN182468B publication Critical patent/IN182468B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
IN102MA1996 1995-01-20 1996-01-19 IN182468B (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (1)

Publication Number Publication Date
IN182468B true IN182468B (cg-RX-API-DMAC7.html) 1999-04-17

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
IN102MA1996 IN182468B (cg-RX-API-DMAC7.html) 1995-01-20 1996-01-19

Country Status (40)

Country Link
US (1) US6107302A (cg-RX-API-DMAC7.html)
EP (1) EP0804436B1 (cg-RX-API-DMAC7.html)
JP (1) JP3176633B2 (cg-RX-API-DMAC7.html)
KR (1) KR100376074B1 (cg-RX-API-DMAC7.html)
CN (1) CN1049893C (cg-RX-API-DMAC7.html)
AP (1) AP662A (cg-RX-API-DMAC7.html)
AR (1) AR002270A1 (cg-RX-API-DMAC7.html)
AT (1) ATE302777T1 (cg-RX-API-DMAC7.html)
AU (1) AU702794B2 (cg-RX-API-DMAC7.html)
BG (1) BG63393B1 (cg-RX-API-DMAC7.html)
BR (1) BR9606768A (cg-RX-API-DMAC7.html)
CA (1) CA2210799C (cg-RX-API-DMAC7.html)
CY (1) CY2531B1 (cg-RX-API-DMAC7.html)
CZ (1) CZ297065B6 (cg-RX-API-DMAC7.html)
DE (1) DE69635106T2 (cg-RX-API-DMAC7.html)
DK (1) DK0804436T3 (cg-RX-API-DMAC7.html)
EA (1) EA000364B1 (cg-RX-API-DMAC7.html)
EE (1) EE03528B1 (cg-RX-API-DMAC7.html)
ES (1) ES2248806T3 (cg-RX-API-DMAC7.html)
FI (1) FI973063A7 (cg-RX-API-DMAC7.html)
GB (1) GB9501178D0 (cg-RX-API-DMAC7.html)
GE (1) GEP20001940B (cg-RX-API-DMAC7.html)
HR (1) HRP960024B1 (cg-RX-API-DMAC7.html)
HU (1) HU222993B1 (cg-RX-API-DMAC7.html)
IL (1) IL116831A (cg-RX-API-DMAC7.html)
IN (1) IN182468B (cg-RX-API-DMAC7.html)
IS (1) IS2268B (cg-RX-API-DMAC7.html)
NO (1) NO315558B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ298851A (cg-RX-API-DMAC7.html)
OA (1) OA10499A (cg-RX-API-DMAC7.html)
PL (1) PL182175B1 (cg-RX-API-DMAC7.html)
RO (1) RO118693B1 (cg-RX-API-DMAC7.html)
RS (1) RS49518B (cg-RX-API-DMAC7.html)
SI (1) SI0804436T1 (cg-RX-API-DMAC7.html)
SK (1) SK285329B6 (cg-RX-API-DMAC7.html)
TR (1) TR199700656T1 (cg-RX-API-DMAC7.html)
UA (1) UA46001C2 (cg-RX-API-DMAC7.html)
UY (1) UY25779A1 (cg-RX-API-DMAC7.html)
WO (1) WO1996022291A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA96449B (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
DK0874631T3 (da) * 1996-01-19 2004-03-22 Glaxo Group Ltd Anvendelse af valaciclovir til fremstilling af et medikament til behandling af genital herpes ved en enkelt daglig anvendelse
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
WO1998031683A1 (en) * 1997-01-17 1998-07-23 Ajinomoto Co., Inc. Novel z-valacyclovir crystals
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
DK1757606T3 (da) * 2001-02-24 2009-09-07 Boehringer Ingelheim Pharma Anvendelse af xanthinderivater som l gemidler samt fremgangsm de til deres fremstilling
PL374179A1 (en) * 2001-09-07 2005-10-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
JP2005511612A (ja) * 2001-11-05 2005-04-28 グラクソ　グループ　リミテッド 塩酸バラシクロビルの無水結晶形
IL161969A0 (en) * 2001-11-14 2005-11-20 Teva Pharma Synthesis and purification of valacyclovir
US20060147519A1 (en) * 2002-06-24 2006-07-06 Ashish Gogia Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003277433A1 (en) * 2002-10-16 2004-05-04 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004052892A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
EP1633753A1 (en) * 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
KR100871621B1 (ko) 2003-06-02 2008-12-02 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르 히드로클로라이드의 신규한 결정질 형태
KR20060117355A (ko) * 2004-01-21 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로버 염산염의 제조 방법
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
EP1891071B1 (en) * 2005-05-25 2012-02-22 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5323684B2 (ja) * 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
EP2326326B1 (en) * 2008-08-15 2019-10-09 Boehringer Ingelheim International GmbH Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
WO2013076688A1 (en) * 2011-11-25 2013-05-30 Piramal Enterprises Limited A process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
ATE199719T1 (de) * 1993-06-10 2001-03-15 Rolabo Sl Verfahren zur herstellung von aminosäureester von nukleosid analogen
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
AU702794B2 (en) 1999-03-04
GEP20001940B (en) 2000-02-05
AR002270A1 (es) 1998-03-11
SK285329B6 (sk) 2006-11-03
WO1996022291A1 (en) 1996-07-25
EP0804436B1 (en) 2005-08-24
NO315558B1 (no) 2003-09-22
ZA96449B (en) 1996-08-07
RS49518B (sr) 2006-10-27
HUP9801836A2 (hu) 1999-05-28
FI973063L (fi) 1997-09-18
HUP9801836A3 (en) 1999-06-28
IL116831A0 (en) 1996-05-14
BG101833A (bg) 1998-04-30
CZ229497A3 (en) 1997-12-17
YU3396A (sh) 1998-12-23
CA2210799C (en) 2008-06-10
ES2248806T3 (es) 2006-03-16
HRP960024B1 (en) 2005-08-31
EP0804436A1 (en) 1997-11-05
AP662A (en) 1998-08-19
CY2531B1 (en) 2006-04-12
IL116831A (en) 1998-10-30
EE9700175A (et) 1998-02-16
PL182175B1 (pl) 2001-11-30
HRP960024A2 (en) 1997-10-31
KR19980701525A (ko) 1998-05-15
FI973063A7 (fi) 1997-09-18
SI0804436T1 (sl) 2006-02-28
FI973063A0 (fi) 1997-07-18
PL321326A1 (en) 1997-12-08
GB9501178D0 (en) 1995-03-08
EA000364B1 (ru) 1999-06-24
UY25779A1 (es) 2000-08-21
BR9606768A (pt) 1997-12-30
HU222993B1 (hu) 2004-01-28
IS4527A (is) 1997-07-15
NO973326D0 (no) 1997-07-18
NZ298851A (en) 1999-01-28
DE69635106D1 (de) 2005-09-29
CA2210799A1 (en) 1996-07-25
EE03528B1 (et) 2001-10-15
CZ297065B6 (cs) 2006-08-16
KR100376074B1 (ko) 2003-06-02
SK96597A3 (en) 1998-02-04
JPH11503718A (ja) 1999-03-30
DK0804436T3 (da) 2005-12-27
IS2268B (is) 2007-07-15
CN1179159A (zh) 1998-04-15
DE69635106T2 (de) 2006-06-08
EA199700124A1 (ru) 1997-12-30
ATE302777T1 (de) 2005-09-15
MX9705462A (es) 1997-10-31
OA10499A (en) 2002-04-10
US6107302A (en) 2000-08-22
TR199700656T1 (xx) 1998-03-21
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
NO973326L (no) 1997-09-16
RO118693B1 (ro) 2003-09-30
JP3176633B2 (ja) 2001-06-18
UA46001C2 (uk) 2002-05-15
AP9701058A0 (en) 1997-10-31
AU4453996A (en) 1996-08-07

Similar Documents

Publication Publication Date Title
BRPI9612258B1 (cg-RX-API-DMAC7.html)
BRPI9612138B1 (cg-RX-API-DMAC7.html)
CH0741373H1 (cg-RX-API-DMAC7.html)
IN184621B (cg-RX-API-DMAC7.html)
BR7501503U (cg-RX-API-DMAC7.html)
BR7502120U (cg-RX-API-DMAC7.html)
IN183494B (cg-RX-API-DMAC7.html)
CN3032332S (cg-RX-API-DMAC7.html)
CN3032692S (cg-RX-API-DMAC7.html)
CN3029928S (cg-RX-API-DMAC7.html)
CN3030154S (cg-RX-API-DMAC7.html)
CN3030197S (cg-RX-API-DMAC7.html)
CN3030225S (cg-RX-API-DMAC7.html)
CN3030296S (cg-RX-API-DMAC7.html)
CN3030415S (cg-RX-API-DMAC7.html)
CN3030489S (cg-RX-API-DMAC7.html)
CN3030542S (cg-RX-API-DMAC7.html)
CN3030543S (cg-RX-API-DMAC7.html)
CN3030760S (cg-RX-API-DMAC7.html)
CN3031001S (cg-RX-API-DMAC7.html)
CN3031350S (cg-RX-API-DMAC7.html)
CN3031655S (cg-RX-API-DMAC7.html)
CN3031742S (cg-RX-API-DMAC7.html)
CN3031926S (cg-RX-API-DMAC7.html)
BY5258C1 (cg-RX-API-DMAC7.html)